If you have been reading about Reference standard and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-30. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Although the term "wet market" may refer to markets that sell wild animals and wildlife products, it is not synonymous with the term "wildlife market" which exclusively refers to markets that contain wildlife products.
In non-small cell lung cancer, both mRNA and protein levels of TMPRSS11D are elevated in tumor tissue compared with adjacent normal tissue, and high protein expression is an independent predictor of poorer overall survival. Plasminogen (PLG), from which originates the mini-plasmin that can cleave the F-protein, is highly expressed in liver cancers. Its expression is also increased in a wide range of other malignant neoplasms. Factor X (F10) is frequently expressed in normal liver and in liver cancers. SeV constructs were created with a modified protease cleavage site. The modification allowed the recombinant virus to specifically infect cancer cells that expressed the corresponding proteases, which can cleave a modified protease cleavage site.
To correct a defect of the nasal lining of the upper two-thirds of the nose, the wound dimensions (length, width, depth) determine the technique. A nasal-lining defect of less than 5 mm in diameter can be closed primarily, with sutures. A nasal-lining defect 5–15 mm in diameter can be closed with a random transposition flap harvested from a nasal area that remains protected, either by the nasal bones or by the upper lateral cartilages; and the flap donor-site can be healed by secondary intention, re-epithelialisation. For a mucosa defect greater than 15 mm in diameter, the indicated correction is a superiorly based "trap door" septal mucosal flap, grafted to the roof of the nasal septum. (c) Nasal tip defect The width of the human nasal-tip ranges 20–30 mm; the average width of the nasal tip, measured between the two alar lobules, is approximately 25 mm.
Sources: en.wikipedia.org
Perforin's role in protecting the body against lymphoma was emphasized when scientists discovered that p53 did not have as big of a role in lymphoma surveillance as its counterpart perforin. Perforin and granzymes have been found to have a directly related ability to protect the body against the formation of different kinds of lymphomas.
The enzyme converts the trans double bond of a thioester attached to an acyl carrier protein to the corresponding saturated compound using nicotinamide adenine dinucleotide phosphate (NADPH) and a proton as reducing agent. This enzyme belongs to the family of oxidoreductases, to be specific, those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is acyl-[acyl-carrier-protein]:NADP+ oxidoreductase (B-specific). Other names in common use include acyl-ACP dehydrogenase, reductase, enoyl-[acyl carrier protein] (reduced nicotinamide, adenine dinucleotide phosphate), NADPH 2-enoyl Co A reductase, enoyl acyl-carrier-protein reductase, enoyl-ACP reductase, and enoyl-[acyl-carrier-protein] reductase (NADPH, B-specific). This enzyme participates in fatty acid biosynthesis.
=== Domain-pair exclusion analysis === The domain-pair exclusion analysis detects specific domain interactions that are hard to detect using Bayesian methods. Bayesian methods are good at detecting nonspecific promiscuous interactions and not very good at detecting rare specific interactions. The domain-pair exclusion analysis method calculates an E-score which measures if two domains interact. It is calculated as log(probability that the two proteins interact given that the domains interact/probability that the two proteins interact given that the domains don’t interact). The probabilities required in the formula are calculated using an Expectation Maximization procedure, which is a method for estimating parameters in statistical models. High E-scores indicate that the two domains are likely to interact, while low scores indicate that other domains form the protein pair are more likely to be responsible for the interaction. The drawback with this method is that it does not take into account false positives and false negatives in the experimental data.
=== Age === Age estimation attempts to determine the skeletal/biological age-at-death. The primary assumption is that an individual's skeletal age is closely associated with their chronological age. Age estimation can be based on patterns of growth and development or degenerative changes in the skeleton. A variety of skeletal series methods to assess these types of changes have been developed. For instance, in children age is typically estimated by assessing dental development, ossification and fusion of specific skeletal elements, or long bone length. For children, different teeth erupt from the gums serially are the most reliable for telling a child's age. However, fully developed teeth are less indicative. In adults, degenerative changes to the pubic symphysis, the auricular surface of the ilium, the sternal end of the 4th rib, and dental attrition are commonly used to estimate skeletal age. Until the age of about 30, human bones keep growing. Different bones fuse at different points of growth. This development can vary across individuals. Wear and tear on bones further complicates age estimates. Often, estimates are limited to 'young' (20–35 years), 'middle' (35–50 years), or 'old' (50+ years).
Sources: en.wikipedia.org
Abdominal obesity is typically associated with a statistically higher risk of heart disease, hypertension, insulin resistance, and type 2 diabetes (see below). With an increase in the waist to hip ratio and overall waist circumference the risk of death increases as well. Metabolic syndrome is associated with abdominal obesity, blood lipid disorders, inflammation, insulin resistance, type 2 diabetes, and an increased risk of developing cardiovascular disease. It is now generally believed that intra-abdominal fat is the depot that conveys the biggest health risk. Recent validation has concluded that total and regional body volume estimates correlate positively and significantly with biomarkers of cardiovascular risk and that BVI calculations correlate significantly with all biomarkers of cardiovascular risk. Abdominal obesity is linked with higher cardiovascular events among South Asian ethnic populations.
Production of gold In 2022, the RILIS, Windmill and ISOLTRAP teams reported producing 18 gold nuclei from proton bombardment of a uranium target. Discovery of beta-delayed multi-particle emission The first observation of beta-delayed two-neutron emission was made at ISOLDE in 1979, using the isotope lithium-11. Beta-delayed emission occurs for isotopes further away from the line of stability, and involves particle emission after beta decay. Newer studies have been proposed to investigate beta-delayed multi-particle emission of lithium-11 using the IDS.
Each Equip issue discussed the state of a particular games platform, looking back on significant releases with the benefit of hindsight and outlining future developments. For example, the GameCube issue featured lengthy retrospectives on The Legend of Zelda: The Wind Waker and Animal Crossing, plus a feature on upcoming titles that would use the GameCube – Game Boy Advance link cable. 'Specials issue ten: "Retro: The Collector's Series" This final edition in the Retro series reprinted all of the "Collector's Series" of articles from the main magazine. Each feature focused on a specific video game console of yesteryear and examined its history and the collectors market surrounding its rare or collectable games. Unusually for Edge, the majority of these articles were written by one video games journalist: Simon Parkin, a long-time freelance contributor to the magazine. "Edge presents FILE Volume 1 - Issues 1-12: The birth of a new generation" (2006) "Edge presents FILE Volume 2 - Issues 13-24: The new generation shows its strength" (2007) "Edge presents FILE Volume 3 - Issues 25-36: Videogame culture enters a new era" (2007)
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.